Gross-To-Net FOMO:

What GTN Dangers Are You Missing Post-Launch?

In his more than 25-year career, Chris has become a recognized voice in the patient affordability and specialty medication arena, pioneering prominent copay and patient affordability programs, and creating innovative solutions for his clients.

A recognized leader in the space, Dowd has been on the forefront of virtually every development in the patient copay industry over the past decade.

Chris leads strategic market analysis and product go-to-market strategies at ConnectiveRx.

Patrick R. Coyle is a life sciences Executive and Gross-to-Net (GTN) thought leader. With leadership experience spanning Bayer, Novartis, Insmed, Eisai, IQVIA, Baker Tilly, and entrepreneurial ventures, he specializes in connecting patient access, commercialization strategy, and financial sustainability.

Patrick has spent his career helping pharmaceutical and biotechnology companies navigate the increasingly complex intersection of healthcare economics, reimbursement, market access, GTN, patient support, and launch readiness. His unique perspective bridges the traditional divide between commercial and finance organizations, creating a shared understanding of how decisions made across the healthcare ecosystem ultimately impact both patient outcomes and business performance.

As Founder of NextGen GTN™, Patrick is developing the next generation of commercialization education through training, workshops, and thought leadership designed to help organizations align the commercial "Side A" and finance "Side B" of the vinyl.

Through Novus Proximus LLC, he advises life sciences organizations on channel redesign, GTN operations, patient access strategies, and profitability optimization.

His guiding philosophy is simple:

Patients + Profitability™ are not competing priorities, they are the same mission.